# RPSA as a Potential Prognostic Biomarker of Pancreatic Cancer

> **NCT04575363** · NA · RECRUITING · sponsor: **CHU de Reims** · enrollment: 90 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma (PDAC)

## Interventions

- **OTHER:** Blood sample

## Key facts

- **NCT ID:** NCT04575363
- **Lead sponsor:** CHU de Reims
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-18
- **Primary completion:** 2026-10-18
- **Final completion:** 2027-10-18
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2023-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04575363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04575363, "RPSA as a Potential Prognostic Biomarker of Pancreatic Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04575363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*